# 2026-09808: NIH Licenses Supercharged Cancer Drug Combo for Better Fights

2026-09808, Government Owned Inventions Available for License: Synergistic Interactions for Improved Cancer Treatment, is a Federal Register notice from Health and Human Services Department, National Institutes of Health published 2026-05-15, effective 2026-05-15 (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-09808
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-09808
- Title: Government Owned Inventions Available for License: Synergistic Interactions for Improved Cancer Treatment
- Type: Notice
- Agencies: Health and Human Services Department; National Institutes of Health
- Citation: 91 FR 27968
- Published: 2026-05-15
- Effective: 2026-05-15
- Comments close: not stated
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

NIH Licenses Supercharged Cancer Drug Combo for Better Fights

## Summary

The National Cancer Institute is offering a cool new cancer treatment invention called hetIL-15 that works better when combined with other drugs like Fenofibrate or quizartinib. This combo could help patients by making immune cells stronger and safer, potentially wiping out tough cancers like breast and pancreatic tumors. Researchers and companies interested in developing or licensing this breakthrough should act soon to join the fight against cancer.

## Abstract

The National Cancer Institute (NCI) seeks research co- development partners and/or licensees to develop hetIL-15 in combination with other agents, such as PPARa agonists (Fenofibrate), FLT3 inhibitors (quizartinib), IL-12, or chemotherapy into a therapeutic for cancer.

## Effects PRIA read

No economic effects identified for this document.

## Related documents

- [2026-22871](https://policyrisk.com/federal-register/2026-22871): Center for Scientific Review; Notice of Closed Meetings, 2026-11-10
- [2026-22550](https://policyrisk.com/federal-register/2026-22550): Center for Scientific Review; Notice of Closed Meetings, 2026-11-05
- [2026-22558](https://policyrisk.com/federal-register/2026-22558): Center for Scientific Review; Notice of Closed Meetings, 2026-11-05
- [2026-22339](https://policyrisk.com/federal-register/2026-22339): Prospective Grant of Exclusive Patent License: Catheter-Based Intramyocardial Ablation for Treating Ventricular Arrhythmia in a Human, 2026-11-02
- [2026-22196](https://policyrisk.com/federal-register/2026-22196): National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Meeting, 2026-10-30
- [2026-22111](https://policyrisk.com/federal-register/2026-22111): Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Meeting, 2026-10-29

## Sources
- [2026-09808 on federalregister.gov](https://www.federalregister.gov/documents/2026/05/15/2026-09808/government-owned-inventions-available-for-license-synergistic-interactions-for-improved-cancer)
- [2026-09808 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-05-15/pdf/2026-09808.pdf)

## Related
- [Previous: 2026-09807, Foreign Endangered Species; Receipt of Permit Applications](https://policyrisk.com/federal-register/2026-09807)
- [Next: 2026-09809, Request for Comments and Public Hearing About the Administration's Action Follo…](https://policyrisk.com/federal-register/2026-09809)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-09808 (as of 2026-06-08).
